Tatva Chintan Pharma promoters confirm zero share encumbrance in FY26
Promoters of Tatva Chintan Pharma Chem Limited declared that no shares were encumbered directly or indirectly during the financial year ended March 31, 2026. The filing, made by Shekhar Rasiklal Somani under Regulation 31(4) of the SEBI SAST Regulations, 2011, lists 13 promoter group entities including individuals and corporate bodies. The disclosure confirms that the promoter group has not pledged any holdings during this period.

*this image is generated using AI for illustrative purposes only.
Promoters of tatva chintan pharma have confirmed that no shares of the company were encumbered directly or indirectly during the financial year ended March 31, 2026. The declaration, submitted to the stock exchanges, assures stakeholders that the promoter group has not pledged any holdings during this period, thereby mitigating potential risks associated with promoter pledging.
The disclosure was filed on April 1, 2026, pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Shekhar Rasiklal Somani, a promoter of the company, made the declaration on behalf of himself and other persons acting in concert. The filing was addressed to the Corporate Relationship Department of BSE Limited and the Listing Department of National Stock Exchange of India Limited.
The promoter group comprises 13 entities, including individuals and corporate bodies. The list includes Shekhar Rasiklal Somani, Kajalben Shekharkumar Somani, and Shitalbhai Rasiklal Somani. Other members include Somani Samir Rasiklal, Aryan Shekhar Somani, Sweny Shekhar Somani, and Archana Chandresh Shah. The group also features Dipali Nitinkumar Mehta and Samir Rasiklal HUF Somani.
Corporate entities within the promoter group include Arete Virtue Jewels, Bakia Laboratories, and Sardar Medical. Additionally, Shekhar Rasiklal Somani Ancestral and Shital R Somani Ancestral are listed as part of the group. The declaration confirms that none of these entities have created any encumbrance on the company's shares during FY26.
A copy of the declaration has been marked to the Chairman and the Audit Committee of the Board of Directors of Tatva Chintan Pharma Chem Limited. The company operates from its registered office located at Plot No 502/17, GIDC Estate, Ankleshwar, Dist. Bharuch, Gujarat.
Historical Stock Returns for Tatva Chintan Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.85% | +2.85% | -5.30% | -14.73% | +26.68% | -48.71% |
How will this zero-pledge status impact investor confidence and the stock's valuation in the upcoming quarters?
Does the promoter group plan to maintain this unencumbered status for the foreseeable future, or are there potential capital needs that might change this?
How does Tatva Chintan's zero-pledge position compare to industry peers, and could it set a new benchmark for corporate governance?


































